Tin tức & Cập nhật
Xem bài viết Dược
Xem
Tremelimumab plus durvalumab safe as first-line treatment for uHCC patients
The use of single tremelimumab (T) regular interval durvalumab (D), or STRIDE, results in a manageable safety profile in Asian patients with unresectable hepatocellular carcinoma (uHCC), as shown by the preliminary results of the SIERRA study.
Tremelimumab plus durvalumab safe as first-line treatment for uHCC patients
17 Jan 2026
Odronextamab plus chemo safe as DLBCL treatment, with promising efficacy
Combination treatment with the CD20×CD3 bispecific antibody odronextamab and chemotherapy is generally safe among previously untreated diffuse large B cell lymphoma (DLBCL) patients, without new safety signals, as shown by the results from part 1 of the phase III Olympia-3 study.
Odronextamab plus chemo safe as DLBCL treatment, with promising efficacy
16 Jan 2026
EPIK-B5 supports alpelisib plus fulvestrant for HR+, HER2– ABC
In the phase III EPIK-B5 study, adding alpelisib, an α-specific PI3K inhibitor, to fulvestrant improves progression-free survival (PFS) in men and postmenopausal women with HR+, HER2− advanced breast cancer (ABC) harbouring a PIK3CA mutation who have progressed on or after treatment with an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i).
